These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32164673)

  • 1. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial.
    Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ;
    Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
    Martinez FJ; Yow E; Flaherty KR; Snyder LD; Durheim MT; Wisniewski SR; Sciurba FC; Raghu G; Brooks MM; Kim DY; Dilling DF; Criner GJ; Kim H; Belloli EA; Nambiar AM; Scholand MB; Anstrom KJ; Noth I;
    JAMA; 2021 May; 325(18):1841-1851. PubMed ID: 33974018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Chen CY; Chen CH; Wang CY; Lai CC; Chao CM; Wei YF
    Respir Res; 2021 Sep; 22(1):243. PubMed ID: 34526011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.
    Kulkarni T; Criner GJ; Kass DJ; Rosas IO; Scholand MB; Dilling DF; Summer R; Duncan SR
    BMC Pulm Med; 2024 Mar; 24(1):143. PubMed ID: 38509495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.
    Wilson EC; Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Twentyman OP; Wilson AM
    Pharmacoeconomics; 2014 Jan; 32(1):87-99. PubMed ID: 24307539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
    Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
    Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Wilson EC; Twentyman OP; Davison AG; Curtin JJ; Crawford MB; Wilson AM
    Thorax; 2013 Feb; 68(2):155-62. PubMed ID: 23143842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM): Protocol for a randomized, pragmatic trial.
    Garrigós C; Rosso-Fernández CM; Borreguero I; Rodríguez P; García-Albea R; Bravo-Ferrer JM; Rodríguez-Baño J; Del Toro MD;
    PLoS One; 2023; 18(5):e0286094. PubMed ID: 37216357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial.
    Hailong Z; Jiansheng L; Wen G; Lu W; Dong Z; Limin Z; Miao Z; Weixian L
    Trials; 2022 Feb; 23(1):103. PubMed ID: 35109889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
    Justice JN; Nambiar AM; Tchkonia T; LeBrasseur NK; Pascual R; Hashmi SK; Prata L; Masternak MM; Kritchevsky SB; Musi N; Kirkland JL
    EBioMedicine; 2019 Feb; 40():554-563. PubMed ID: 30616998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the STRIVE-IPF Trial- Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
    Kulkarni T; Criner GJ; Kass DJ; Rosas IO; Scholand MB; Dilling DF; Summer R; Duncan SR
    Res Sq; 2024 Feb; ():. PubMed ID: 38464052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Yang SG; Yu XQ; Li JS; Xie Y; Zhang W; Ban C; Feng J; Wu L; Lu X; Zhao L; Meng Y; Zhou M; He Y; Luo W
    Trials; 2022 Sep; 23(1):725. PubMed ID: 36056382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.